00:45 , Feb 16, 2019 |  BioCentury  |  Product Development

Embedding digital in Lilly’s portfolio

Eli Lilly and Co. is appointing leaders to drive its digital health agenda, with a strong focus on improving patient outcomes and reducing total healthcare costs. Divakar Ramakrishnan, a 20-year veteran of Lilly, was named...
19:07 , May 2, 2017 |  BC Extra  |  Financial News

Tetragenetics gets JDRF investment

JDRF T1D Fund invested an undisclosed amount in Tetragenetics Inc. (Cambridge, Mass.), the company said. Tetragenetics is developing mAbs targeting potassium channel Kv1.3 (KCNA3) to treat Type I diabetes. Tetragenetics said that by targeting ion...
21:50 , Mar 22, 2017 |  BC Extra  |  Financial News

Semma receives JDRF investment

Cell therapy company Semma Therapeutics Inc. (Cambridge, Mass.) said it received an undisclosed investment from the JDRF T1D Fund. Semma CEO Robert Millman told BioCentury that the investment, which took the form of a convertible...
00:08 , Jan 28, 2017 |  BioCentury  |  Finance

Spotlight on T1D

With a planned $80 million fund, JDRF aims to attract a wave of investment from VCs and strategic investors to early stage Type I diabetes companies. JDRF announced the first close of the JDRF T1D...
21:05 , Jan 27, 2017 |  BC Week In Review  |  Financial News

Bigfoot Biomedical completes venture financing

On Jan. 26, drug delivery company Bigfoot Biomedical Inc. (Milpitas, Calif.) raised an undisclosed amount in a venture round from JDRF T1D Fund. Bigfoot Biomedical Inc. , Milpitas, Calif. ...
00:19 , Jan 27, 2017 |  BC Extra  |  Financial News

JDRF launches venture philanthropy fund

Diabetes charity JDRF launched the JDRF T1D Fund, a venture philanthropy fund designed to invest in companies with early stage programs focused on Type I diabetes treatment and prevention. The planned $80 million fund has...